Juvenescence

Executive Summary

Juvenescence is a UK-based clinical-stage biotechnology company founded in 2016 with a mission to extend healthy human lifespan by targeting fundamental biological mechanisms of aging. The company employs a multimodal therapeutic approach, combining small molecules and biologics to intervene early in age-related diseases. Although still early-stage (Phase 1), Juvenescence has assembled a platform that addresses aging as a modifiable risk factor, differentiating it from traditional disease-specific biotechs. Its pipeline focuses on novel targets in cellular senescence, metabolism, and inflammation, with lead candidates in development for conditions such as neurodegenerative and metabolic disorders. The company is privately held and has not disclosed total funding or valuation, but its scientific premise and experienced team position it as a notable player in the longevity space.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 data readout for lead senolytic candidate in age-related indications40% success
• Q4 2026Initiation of Phase 2 trial for metabolic aging target35% success
• 2026Strategic partnership or licensing deal for AI-driven drug discovery platform50% success